Phase Ib Study of Tisagenlecleucel in Combination With Pembrolizumab in Relapsed/Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) Patients.
Phase of Trial: Phase I
Latest Information Update: 15 May 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Tisagenlecleucel (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms PORTIA
- Sponsors Novartis Pharmaceuticals
- 21 Feb 2019 Planned End Date changed from 27 Feb 2023 to 8 Sep 2023.
- 21 Feb 2019 Planned primary completion date changed from 28 Oct 2019 to 28 Feb 2020.
- 29 Aug 2018 Status changed from not yet recruiting to recruiting.